naratriptan NDC 23155-055

NDC codes

FDA NDC Directory

Product NDC (as listed)23155-055Labeler and product segments. Claims need a package NDC.

Product NDC at billing width23155-0055Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
23155-055-03	23155005503	30 TABLET in 1 BOTTLE (23155-055-03)Marketed from Mar 15, 2011
23155-055-05	23155005505	500 TABLET in 1 BOTTLE (23155-055-05)Marketed from Mar 15, 2011
23155-055-19	23155005519	9 TABLET in 1 BLISTER PACK (23155-055-19)Marketed from Mar 15, 2011

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): naratriptan
Generic name (nonproprietary): naratriptan
Active ingredients: Naratriptan hydrochloride — 2.5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 200502
Marketing start: Mar 15, 2011
Listing expires: Dec 31, 2026
Other FDA classes: Serotonin 1b Receptor Agonists (Mechanism)Serotonin 1d Receptor Agonists (Mechanism)
Identifiers: Product ID 23155-055_61e37b1d-f036-4c35-9073-ce456efd8007SPL ID 61e37b1d-f036-4c35-9073-ce456efd8007SPL set ID 41c29652-32f8-48dc-9038-0e2195aa2084RxCUI 311918, 314135UNII 10X8X4P12Z
Pharmacologic class: Serotonin-1b and Serotonin-1d Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N423155005503 followed by a unit qualifier and the quantity

Package 23155-0055-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 30, 2025.

Indications (excerpt from the label)

Naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan tablets reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. Naratriptan tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of naratriptan tablets have not been established for cluster headache. Naratriptan Tablets are serotonin (5-HT 1B/1D ) receptor agonists (triptan) indicated for the acute treatment of migraine with or witho…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 200502

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 200502
Product	Strength	Form · route	Labeler	Product NDC
naratriptan	Naratriptan hydrochloride 1 mg/1	TabletOral	ASCLEMED USA INC.	87063-287
naratriptan	Naratriptan hydrochloride 2.5 mg/1	TabletOral	ASCLEMED USA INC.	87063-288
naratriptan	Naratriptan hydrochloride 1 mg/1	TabletOral	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	23155-054